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SUMMARY – Vascular dementia is caused by progressive atherosclerosis leading to multiple small 
strokes and subsequent brain damage. Approximately 10%-20% of all cases of dementia are attributed 
to vascular dementia. The 5-year survival rate is 39% for patients with vascular dementia compared 
with 75% for age-matched controls. It is a growing public health concern because of the lack of effec-
tive curative treatment options and rising global prevalence. Duration of diabetes mellitus of 10 years 
or longer, onset of diabetes before age 65, treatment with insulin and oral antidiabetic medications, 
and presence of diabetes complications have an impact on the incidence of vascular dementia. On the 
other hand, patients who suffered stroke either had or are later diagnosed with diabetes (16%-24%). 
Treatment of vascular dementia in diabetes patients rests on a two-pronged approach: modification of 
the underlying disease and prevention and treatment of dementia symptoms.
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Epidemiology
Vascular dementia is caused by progressive athero-
sclerosis leading to multiple small strokes and subse-
quent brain damage. Approximately 10%-20% of all 
cases of dementia are attributed to vascular dementia 
(immediately following Alzheimer’s disease account-
ing for 60%-70% of all dementia patients). The 5-year 
survival rate is 39% for patients with vascular demen-
tia compared with 75% for age-matched controls. It is 
a growing public health concern because of the lack of 
effective curative treatment options and rising global 
prevalence. The main subtypes of this disease are mild 
cognitive impairment, multi-infarct dementia, vascu-
lar dementia due to a strategic single infarct (affecting 
the thalamus, the anterior cerebral artery, the parietal 
lobes or the cingulate gyrus), vascular dementia due 
to hemorrhagic lesions, small vessel disease (which 
includes vascular dementia due to lacunar lesions and 
Binswanger’s disease), mixed Alzheimer’s and vascu-
lar dementia1,2.
Common risk factors for this type of dementia are 
the same as for cerebrovascular disease and include 
unmodifiable risk factors of age, gender, race/ethnici-
ty, genotype, previous myocardial infarction, transient 
ischemic attack (TIA) or stroke, and modifiable risk 
factors of diabetes, hyperlipidemia, arterial hyperten-
sion, atrial fibrillation, coronary and/or peripheral ar-
tery disease, obesity, physical inactivity, stress, alcohol 
consumption and smoking2.
Association of Diabetes Mellitus and Dementia
Recent estimates on the prevalence of diabetes mel-
litus (DM, type 1 and type 2) have indicated diagnostic 
rates for adults over age 60 at 12%-20%. Approximately 
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90% of these cases are type 2 diabetes. Studies have 
examined whether adverse cognitive effects of diabe-
tes are broad or selective across domains. Verbal epi-
sodic memory is typically (but not uniformly) affected 
in diabetic patients. Diabetes related slowing has been 
observed with a variety of speed tasks, especially those 
measuring basic reaction time or perceptual speed, as 
well as executive functioning2-6. Association between 
DM and cognitive decline implies the following: du-
ration of DM of 10 years or longer (odds ratio (OR) 
1.76; 95%CI 1.16-2.68); onset of diabetes before age 
65 (OR 2.20; 95%CI 1.29-3.73); treatment with in-
sulin (OR 2.01; 95%CI 1.22-3.31); oral antidiabetic 
medications (OR 3.6; 95%CI 1.3-9.5); presence of 
diabetes complications (OR 1, 80; 95%CI 1.13-2.89); 
patients who suffered stroke either had or are later di-
agnosed with DM (16%-24%)7,9. 
Patients with diabetes are at a 1.5- to 3-fold risk of 
stroke compared with general population, and associ-
ated mortality and morbidity are greater than in those 
without this underlying condition. Even patients with 
a metabolic syndrome component have a 1.5-fold 
increased risk of stroke (Table 1)7-11. The Rotterdam 
study (6370 subjects) has shown that the diabetes at-
tributable risk of vascular dementia is 8.8% (1.5-fold 
greater risk) and that lipoprotein associated phospho-
lipase A2 (Lp-PLA2) is a new marker for atheroscle-
rosis and cognitive decline12.
The Kungsholmen project (1301 subjects) has 
shown a 2.6 (95%CI 1.2-1.6) hazard ratio for diabetic 
patients to develop vascular dementia. Hazard ratio 
was higher in diabetic patients with severe systolic 
hypertension or heart disease13. A Canadian study 
of health and aging (5574 subjects) has shown that 
DM is associated with vascular dementia (relative 
risk=2.03; 95%CI, 1.5-3.57)14. The Action to Control 
Cardiovascular risk in Diabetes-Memory in Diabetes 
(ACCORD-MIND; 2977 subjects) trial has shown 
that a 1% higher HbA1c value was associated with 
significant 1.75 (95%, -1.22 to -2.28) point Digital 
Symbol Substitution Test (DSST) score, 0.20 (-0.11 
to -0.28; p<0.0001) lower Mini Mental State Exam 
(MMSE) score, 0.11 point lower memory score (-0.02 
to -0.19, p=0142) and worse score on the Stroop test 
(1.31-0.19, p=0.0094)15.
The Longitudinal Aging Study Amsterdam (1183 
subjects) and Honolulu Asia Aging study have shown 
that metabolic syndrome affects cognitive decline 
(p<0.05), especially in individuals with higher C-
reactive protein and interleukin-6 values (inflamma-
tion) and higher glycemia values (hyperglycemia)9. A 
study on 7402 men has shown that body mass index 
values less than 20 and 22.5 or higher are associated 
with an increased risk of middle to old age diagnosis 
of dementia9.
Genetic host contribution to blood vessel suscepti-
bility to hypertensive damage was demonstrated in the 
NHLBI Twin Study (71% heritability for leukoaraio-
sis), as well as in the Framingham and GENOA stud-
ies. The Framingham Heart Study has shown stroke 
related genes on chromosome 4p (odds score 3.69) and 
chromosome 17 (odds score 1.78). COL4A1 gene was 
proved to have a role in small vessel disease4-6.
Pathophysiology
The exact neuroanatomical or neurochemical ef-
fects of diabetes on cognitive performance are relatively 
unknown. Some studies suggest that frontal structures 
may be affected and may therefore be associated with 
deficits of episodic memory recall, verbal fluency, and 
executive functioning. Additionally, reduced volumes 
of the amygdale and the hippocampus in diabetes pa-
tients may underline deficits associated with learning 
and memory. Recent reports on magnetic resonance 
imaging abnormalities and cognitive changes found 
with white matter lesions and subcortical atrophy in 
type 2 diabetes patients suggest an accelerated rate of 
age-related structural changes. Other risk factors for 
cerebrovascular disease as comorbidities in diabetes 
patients may accelerate these structural changes and 
cognitive decline1-4.
Generally, vascular complications of diabetes can 
be separated into microvascular (diabetic nephropa-
thy, neuropathy and retinopathy) and macrovascular 
(coronary disease, cerebrovascular disease, peripheral 
artery disease) complications. These complications are 
primarily due to increased proatherogenic risk fac-
tors in diabetic patients, i.e. abnormal plasma lipid 
profiles, hypertension, and hyperglycemia. However, 
other pathological features associated with diabetes, 
such as insulin resistance and hyperinsulinemia, also 
lead to atherosclerotic changes in extracranial and in-
tracranial vessels independently of glycemia or other 
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attendant risk factors. This is particularly expressed 
in smaller cerebral vessels increasing the incidence of 
both overt and silent lacunar infarctions. The central 
pathomorphological mechanism in these complica-
tions is atherosclerosis which leads to narrowing of 
arterial walls throughout the body. Atherosclerosis 
is thought to result from chronic inflammation and 
injury to the arterial wall in the peripheral, coronary 
or cerebrovascular system. In response to endothelial 
injury and inflammation, oxidized lipids from low 
density lipoprotein (LDL) particles accumulate in the 
endothelial part of the vessel wall. Angiotensin II may 
promote the oxidation of such particles. Monocytes 
then infiltrate the arterial wall and differentiate into 
macrophages, which accumulate oxidized lipids to 
form foam cells. Once formed, foam cells stimulate 
macrophage proliferation and attraction of T-lympho-
cytes. T-lymphocytes, in turn, induce smooth muscle 
proliferation in the arterial wall and collagen accumu-
lation. The net result of the process is the formation of 
a lipid-rich atherosclerotic lesion with a fibrous cap. 
Rupture of this lesion leads to acute vascular infarc-
tion; these ruptures and bleeding into the plaque are 
more frequent in diabetic patients (diabetic patients 
have a higher perioperative risk of carotid endart-
erectomy as well). In addition to atheroma formation, 
there is strong evidence for increased platelet adhe-
sion, hypercoagulability, impaired nitric oxide gen-
eration and increased free radical formation, as well as 
altered calcium regulation in diabetic patients4-16.
Differential Diagnosis
The onset of vascular dementia goes unnoticed in 
the early stages; sometimes symptoms such as cogni-
tive and intellectual impairment as well as carrying 
out everyday activities may become apparent only in 
the mid-to-late stages. The symptoms of dementia 
include memory loss, confusion, forgetfulness, poor 
concentration, inability to cope with everyday activi-
ties, language impairment, slurred speech, inability to 
follow simple instructions, laughing and crying inap-
propriately, behavioral changes, impaired social skills, 
eating problems, a shuffling or jerky gait, incontinence 
and/or lack of bowel control. Lateralizing signs such 
as hemiparesis, bradykinesia, hyperreflexia, ataxia, 
pseudobulbar palsy, and gait and swallowing difficul-
ties may also be observed1,4,9.
Several specific diagnostic criteria can be used to 
diagnose vascular dementia, as follows: Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edi-
tion (DSM-IV) criteria; International Classification 
of Diseases, Tenth Edition criteria; National Institute 
of Neurological Disorders and Stroke – Association 
International pour la Recherché et L’Enseignement 
en Neurosciences (NINDS-AIREN) criteria; The 
Alzheimer’s Disease Diagnostic and Treatment Cen-
ter criteria; and the Hachinski ischemic score3,4.
Prevention and Treatment
Treatment of vascular dementia in diabetes patients 
rests on a two-pronged approach: modification of the 
underlying disease and prevention and treatment of 
dementia symptoms. These include intensive glucose 
control (HbA1c ≤7 mmol/L) with diabetic diet, oral 
antidiabetic agents or insulin, particularly when insti-
tuted early in diabetes patients, and delay or prevent 
clinically manifest cognitive changes. There is still no 
cure for vascular dementia, as pharmacotherapy can 
only treat the symptoms and control underlying mod-
ifiable risk factors14.
The goals of pharmacotherapy should be as fol-
lows: primary and secondary prevention of cognitive 
changes in diabetes patients; reduction of the existing 
cognitive changes with acceptable pharmacotherapy 
side effects; restoration/improvement in functional 
measures and quality of life14.
Various potential risk or preventive factors for vas-
cular dementia have been suggested by epidemiologi-
cal research: lifestyle changes including diet, physical 
activity and stress reduction, as well as pharmacologi-
cal strategies such as antihypertensive drugs, statins, 
antiplatelet and anticoagulant therapy, antidiabetic 
drugs, insulin, hormone replacement therapy, non-
steroidal antiinflammatory drugs (NSAID), Ginkgo 
biloba, ENADPH, donepezil, galantamine, meman-
tine, rivastigmine, cyclandelate, hydergine, pentoxi-
fylline, and CDP choline.
Glycemic control has a high impact on vascular 
remodeling. The Insulin Resistance Atherosclerosis 
Study (IRAS) has shown that diabetes and glucose in-
tolerance are independent risk factors connected with 
Acta Clin Croat,  Vol. 53,   No. 3,  2014 329
Iris Zavoreo et al. Vascular dementia and diabetes mellitus
an increase in the intima media thickness (IMT)17. 
The SANDS trial (The Stop Atherosclerosis in Native 
Diabetics Study) has shown that reduction in other 
cerebrovascular risk factors (hypertension, hyperlipo-
proteinemia) can slower progression of IMT thicken-
ing in diabetic patients18.
Polyvitamin and antioxidant intake as well as diet 
are important in the treatment of vascular dementia. 
The Folic Acid and Carotid IMT (FACIT) study has 
shown that folic acid supplementation has beneficial ef-
fect on global cognitive functions19. Meta-analyses have 
shown that the intake of vitamin B6, vitamin B12, 
folate, antioxidants (vitamin C and E, beta-carotene, 
flavonoids, selenium and other), reduction of homo-
cysteine levels in plasma, as well as the intake of poly-
unsaturated fatty acids, Mediterranean diet and physi-
cal activity decrease the risk of cognitive decline20.
Blood pressure control is important in diabetic pa-
tients in order to prevent progression of vascular re-
modeling. The United Kingdom Prospective Diabetes 
Study (UKPDS) has shown that reduction of blood 
pressure (144/82 mm Hg) reduces the risk of cerebro-
vascular disease by 44% versus controls (154/88 mm 
Hg)21,22. The Heart Outcomes Prevention Evaluation 
(HOPE) and Perindopril Protection Against Re-
current Stroke Therapy (PROGRESS) studies have 
shown that angiotensin-converting enzyme (ACE) 
inhibitors reduce stroke incidence9,23. The Losartan 
Intervention For Endpoint reduction in hypertension 
(LIFE) study has shown reduction in stroke incidence 
in patients taking angiotensin receptor blockers24. The 
Anti hypertensive and Lipid lowering Treatment to 
Prevent Heart Attack Trial (ALLAHAT) confirmed 
previous results in diabetic patients with hyperten-
sion15. The Honolulu Asia Aging Study and Cache 
Country study suggest that antihypertensive therapy 
may reduce the risk of dementia and cognitive de-
cline in diabetic patients without previous stroke9,25. 
The Study on Cognition and Prognosis in Elderly 
(SCOPE) has shown that specifically calcium chan-
nel blockers and ACE inhibitors have greatest effect 
in reduction of cognitive decline26.
Statin therapy has also an important role in the 
prevention and treatment of vascular dementia in 
diabetic patients. The Heart Protection Study (HPS; 
5963 diabetic patients, 40 mg simvastatin per day) has 
shown a stroke risk reduction by 24%; the Collabora-
tive Atorvastatin Diabetes study has shown a stroke 
risk reduction by 48% during 3.9 years27-31; the Stroke 
Prevention by Aggressive Reduction in Cholesterol 
Levels study has shown a stroke risk reduction by 10% 
during 5 years; and the Fenofibrate Intervention and 
Event Lowering in Diabetes study has shown similar 
results9,32. Meta-analyses have shown that the adjusted 
relative risk of developing dementia in diabetic patients 
taking statins is 0.29 (0.13-0.63; p=0.002) versus non-
treated individuals (OR 0.79; 95%CI 0.45-1.41)9,27-31.
Antiaggregation therapy was proven as a good 
choice in the prevention of vascular incidents in dia-
betic patients. In the Clopidogrel versus Aspirin in 
Patients at Risk of Ischemic Events (CAPRIE) study, 
aspirin 75-250 mg was proven as the best choice for 
primary and secondary stroke prevention in diabetic 
patients; in case of intolerance or resistance (about 1/5 
of diabetic patients), clopidogrel 75 mg per day can 
be introduced9. According to the European Stroke 
Prevention Study (ESPS), a combination of aspirin 
and dipyridamole should be introduced in diabetic 
patients with recurrent strokes7. The Clopidogrel for 
High Atherothrombotic Risk and Ischemic Stabili-
zation, Management and Avoidance (CHARISMA) 
study did not show any better effect of taking a combi-
nation of aspirin and clopidogrel versus either of these 
medicines as monotherapy33. The Management of 
Atherothrombosis with Clopidogrel in High-risk pa-
tients with recent TIA or ischemic stroke (MATCH) 
study included 7599 patients, 68% of them diabet-
ics34. Meta-analyses have shown that long-term use 
of NSAID reduces the risk of dementia, whereby the 
type of NSAID is important; the best choice is ace-
tylsalicylic acid in low concentrations (75-100 mg). 




Ischemic/hemorrhagic 10 : 1 5 : 1







Infratentorial stroke Frequent Infrequent
Lacunar stroke Frequent Infrequent
Lesion volume No difference
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Ginkgo biloba has been proven useful in secondary 
prevention of cognitive decline4,9,35,36.
Anticoagulant therapy is recommended in diabetic 
patients with atrial fibrillation. The Warfarin-Aspirin 
ReInfarction Study II (WARIS II) has shown that 
aspirin is better than warfarin in stroke risk reduction 
in diabetic patients with recurrent strokes37.
Long-term plasma glucose control is one of the 
main principles of diabetic treatment, as well as in the 
prevention of vascular complications.
The United Kingdom Prospective Diabetes Study 
(UKPDS) has shown the importance of lifestyle mod-
ification and appropriate diabetic therapy in stroke 
risk reduction, i.e. reduction of HbA1c by 1% reduces 
stroke risk by 4%22. Tight control of glucose is impor-
tant in primary and secondary prevention of cognitive 
decline, in type 2 diabetes (metformin monotherapy 
or add-on therapy with rosiglitazone or glyburide) and 
type 1 diabetes (Diabetes Control and Complications 
study, DCCT)38.
In the Study to Prevent Non-Insulin-Dependent 
Diabetes Mellitus (STOP NIDDM) conducted in 
diabetic patients taking acarbose there was a very low 
stroke incidence (2/682 patients)39. In the Observa-
tional study/Diabetes Control and Complications, 
intensive insulin treatment reduced the rate of any 
vascular incident by 41%38. In the PROspective piogli-
tAzone Clinial Trial in macroVascular Events)-double 
blinded randomized study (PROACTIVE) including 
5238 patients taking 45 mg pioglitazone vs. placebo 
over 34.5 months), pioglitazone reduced the risk of 
stroke in type 2 diabetic patients at a high risk of 
stroke40. Acute glycemic control is of great importance 
in patients with vascular incident. Meta-analyses of 
32 studies have shown that hyperglycemia at admis-
sion (6-8 mmol/L) is a predictor of worse functional 
outcome, and increased 28-day mortality in previ-
ously nondiabetic patients (RR 3.1; 95%CI 2.5-3.8) 
as well in diabetic patients (RR 1.3; 95%CI 0.5-3.4)9. 
The Glucose Insulin in Stroke Trial-Pilot (GIST), In-
sulin in Acute Ischemic stroke (INSULINFARCT) 
and Insulin Resistance Intervention after Stroke Trial 
(IRIS) have shown that there are no differences in 
acute stroke treatment in diabetic patients; of great 
importance is regulation of all metabolic parameters, 
as well as of blood glucose concentration9,38,41.
The aim of the treatment of cognitive decline 
changes is to improve neuronal cell metabolism 
(oxygen supply, microcirculation) and cholinergic 
neurotransmission. Cholinesterase inhibitors, which 
include donepezil, rivastigmine, memantine and gal-
antamine, have proven symptomatic efficacy in Al-
zheimer’s disease and may also have a role in the 
treatment of vascular dementia according to the find-
ings of limited studies. Presently, their use may have 
some justification given the prevalence of dementia 
with mixed pathology. Vasodilators (e.g., hydergine, 
other alkaloids and cyclandelate) have some posi-
tive neuroprotective effect. Modest gains in cogni-
tion have been reported with hemorheological agents 
(pentoxifylline and propentofylline). Calcium chan-
nel blockers, ENADPH, vinca alkaloids, nootropics, 
Table 2. Strategies for prevention of vascular dementia in patients with diabetes mellitus
  1. Treat diabetes optimally 
  2. Treat hypertension optimally 
  3. Control hyperlipidemia 
  4. Persuade patients to cease smoking and decrease alcohol intake 
  5. Prescribe anticoagulants for atrial fibrillation 
  6. Provide antiplatelet therapy for high risk patients 
  7. Perform carotid endarterectomy for severe (>70%) carotid stenosis 
  8. Use dietary control for diabetes, obesity and hyperlipidemia 
  9. Recommend lifestyle changes (e.g., weight loss, exercise, reduce stress, decrease salt intake)
10. Intervene early for stroke and transient ischemic attacks with neuroprotective agents (e.g., propentofylline, 
calcium channel antagonists, N-methyl-D-aspartate receptor antagonists, antioxidants) 
11. Provide intensive rehabilitation after stroke
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and extracts of Ginkgo biloba may improve memory 
in vascular dementia patients42-44. A summary of the 
main strategies in the prevention and treatment is 
shown Table 2. 
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Sažetak
VASKULARNI KOGNITIVNI POREMEćAJ U ŠEćERNOJ BOLESTI: JESU LI PREVENCIJA 
I LIJEčENJE UčINKOVITI?
I. Zavoreo, Z. Madžar, V. Demarin i V. Bašić Kes
Vaskularna demencija nastaje kao posljedica progresivne aterosklerotske bolesti malih krvnih žila mozga uz poslje-
dične višestruke manje moždane udare i oštećenje moždanog parenhima. Oko 10%-20% slučajeva demencije pripisuje 
se vaskularnoj demenciji. Preživljenje bolesnika s vaskularnom demencijom znatno je smanjeno (39%) unutar 5 godina u 
usporedbi s kontrolnom skupinom standardiziranom prema dobi. Dokazana je povezanost šećerne bolesti i kognitivnog 
propadanja u bolesnika sa šećernom bolesti koja traje 10 godina i duže, naročito u slučaju pojavnosti dijabetesa prije 65. 
godine života, liječenja inzulinom ili oralnom antidijabetičkom terapijom te prisutnosti komplikacija dijabetesa. Također 
u bolesnika koji su preboljeli moždani udar postoji povećana pojavnost prethodno ili tijekom hospitalizacije postavljene 
dijagnoze šećerne bolesti (16%-24%). Liječenje bolesnika s vaskularnom demencijom i šećernom bolesti počiva na dva 
dugoročna načela: modifikacija šećerne bolesti te prevencija i liječenje simptoma demencije.
Ključne riječi: Vaskularna demencija – prevencija i kontrola; Vaskularna demencija – terapija; Šećerna bolest - komplikacije
